Summary
PHILADELPHIA -- Federal regulators sued Cephalon Inc. on Wednesday, accusing the company of illegally blocking the sale of low-cost generics to protect its biggest money-making drug.
The U.S. Federal Trade Commission has accused Cephalon of "anti- competitive conduct" by inhibiting generic competition against its drug Provigil. Regulators said the company paid four pharmaceutical firms more than $200 million to halt sales of generic versions of Provigil until 2012. Cephalon produces several products in Salt Lake City, including Actiq.See the full content of this document
Extract
Drug Firm Sued Over Generic Action
Provigil, which accounts for about half of Cephalon's total sales, trea...
See the full content of this document
Sponsored links
